• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Aug. 29, 2017

View Archived Issues

Gilead Sciences flies an $11.9B Kite high into cell therapy, immuno-oncology

John Milligan, president and CEO of Gilead Sciences Inc., pronounced the company’s $11.9 billion acquisition of Kite Pharma Inc. as “a pivot to cellular therapy as our main strategy going forward” but promised that “we’re not going quiet after this deal.” Read More

Financings

Virometix AG, of Schlieren, Switzerland, said it raised CHF1.2 million (US$1.3 million) from new shareholders in an extension to its recent series A financing round. The additional funds will be used to further accelerate development of its vaccine candidates for respiratory syncytial virus and cancer immunotherapy. Read More

News from ESC Congress 2017

Boehringer Ingelheim GmbH, of Ingelheim, Germany, presented data from the phase III RE-DUAL PCI trial testing Pradaxa (dabigatran etexilate mesylate) and a single antiplatelet agent to vitamin K antagonist warfarin and two antiplatelets in 2,727 patients with nonvalvular atrial fibrillation who underwent percutaneous coronary intervention (PCI) with stenting. Read More

Behring down on genetics: $416M Calimmune buyout engrafts key technologies

Calimmune Inc. CEO Louis Breton told BioWorld “a wave is about to crash on the shoreline” for technologies such as those that lured CSL Behring to the table for a buyout deal that included $91 million up front plus milestone payments of as much as $325 million. Read More

Novartis canakinumab cardiovascular outcomes data provoke mixed feelings

DUBLIN – The numbers for the Cantos phase III cardiovascular outcomes trial of Novartis AG’s interleukin-beta1 (IL-beta1) inhibitor, canakinumab, are in. Read More

Atyr raising $45.8M in equity financing to back lung, cancer programs

Atyr Pharma Inc. is raising $45.8 million in equity financing through a private placement expected to help it advance both its pulmonary disease-focused iMod.Fc program and the preclinical Project Orca, an immuno-oncology program from which it plans to identify the project’s first candidate. Read More

FDA hits clinics as Gottlieb addresses regenerative med

The FDA is working under a congressional mandate to adopt a more nimble approach to regulation of regenerative medicine, and the agency has responded with enforcement action against multiple clinics even as FDA Commissioner Scott Gottlieb announced that the agency will “advance a comprehensive policy framework” for regenerative medicine before the end of the calendar year. Read More

Regulatory front

A federal grand jury indictment was unsealed, charging two Texas residents in a scheme involving the sale of second-hand prescription drugs via the U.S. drug supply chain. Read More

Other news to note

Synlogic Inc., of Cambridge, Mass., and Mirna Therapeutics Inc., of Austin, Texas, said their proposed merger closed following the approval of Mirna stockholders on Aug. 24. Read More

In the clinic

Innovation Pharmaceuticals Inc., of Beverly, Mass, said it completed enrollment in its phase IIb trial testing Prurisol (abacavir) in up to 199 patients with moderate to severe psoriasis. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 12, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe